Korean J Dermatol.
2015 Sep;53(8):617-622.
Efficacy and Safety of Ustekinumab in the Treatment of Moderate to Severe Psoriasis in Korea
- Affiliations
-
- 1Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea. dockbs@pusan.ac.kr
- 2Department of Dermatology, Pusan National University of Yangsan Hospital, Yangsan, Korea.
- 3Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
Abstract
- BACKGROUND
Ustekinumab, a fully human monoclonal immunoglobulin antibody that targets the P40 subunit shared by interleukin (IL)-12 and IL-23 has emerged as a promising treatment for moderate to severe psoriasis. However, to date, there are no 'clinical practice setting' data on ustekinumab in Korean patients with psoriasis.
OBJECTIVE
To assess the clinical efficacy and safety of ustekinumab in Korean patients with psoriasis.
METHODS
Prospective data were gathered during the follow-ups of 34 consecutive chronic plaque psoriasis patients treated with ustekinumab for a minimum of 16 weeks at a single referral center. Patients' demographics, Psoriasis Area Severity Index (PASI) score, Physicians' Global Assessment (PGA), Dermatologic Life Quality Index (DLQI), and adverse events were investigated.
RESULTS
The mean PASI score significantly decreased after the first administration of ustekinumab (paired t-test, p<0.05). Twenty-one of 34 patients (61.8%) had obtained near-complete clearance (PASI 90) upon the last follow-up visit. No unexpected adverse events other than herpes zoster and elevated liver enzymes were observed.
CONCLUSION
Ustekinumab can be of benefit in the treatment of Korean psoriasis patients, as it was associated with a rapid and satisfactory response and was well tolerated.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Long-Term Analysis of Ustekinumab Therapy for Moderate-to-Severe Psoriasis in Korea
- Safety of Adalimumab, Ustekinumab, Secukinumab, Guselkumab in Korean Patients with Moderate to Severe Psoriasis: A Real-World Data in a Single Medical Center
- Efficacy and Safety of Ustekinumab in Korean Patients with Moderate-to-severe Psoriasis
- The Effect of Combination Treatment with Ustekinumab and Topical Agents in Korean Patients with Moderate-to-severe Psoriasis: A Retrospective Study of 30 Patients through 5 Years of Follow Up
- Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis
